ArticlePsychopharmacology2026
Neurosteroid (3α,5α)3-hydroxypregnan-20-one enhancement of anti-inflammatory chemokine CX3CL1 exhibits sex, brain region, and cellular specificity in alcohol-preferring rats.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationaleThe neurosteroid [3α,5α]3-hydroxypregnan-20-one (3α,5α-THP) possesses anti-inflammatory properties that modulate chemokine and cytokine expression following the activation of toll-like receptors. The expression of fractalkine (CX3CL1), a chemokine involved in cross-communication in neurons, microglia, and astroglia, varies with 3α,5α-THP treatments, prompting further investigation.
objectivesThis study investigates the influence of 3α,5α-THP on fractalkine expression in neurons, microglia, and astroglia in male and female alcohol-preferring P rats.
methodsDouble-immunofluorescence confocal microscopy against CX3CL1 and markers for neuronal (neuronal nuclear antigen, NeuN), microglial (transmembrane protein 119, TMEM119), and astrocytes (glial fibrillary acidic protein, GFAP) were assessed in the nucleus accumbens (NAc) and central amygdala (CeA) an hour after an intraperitoneal injection of 15 mg/kg 3α,5α-THP.
results3α,5α-THP increases the expression of CX3CL1 in female (41%) and male (52%) CeA, decreases it in female NAc (-37%), and does not alter it in the male NAc. Measuring the shared voxel (intersection) between CX3CL1 and cellular markers revealed that 3α,5α-THP significantly decreases only the intersection of CX3CL1 and NeuN in both female (-32%) and male (-30%) NAc, without affecting the intersection with cellular markers in the CeA. 3α,5α-THP did not alter NeuN, TMEM119, or GFAP expression.
conclusions3α,5α-THP alters the expression of neuronal CX3CL1 in a sex- and brain region-dependent manner. The results clarify the specificity of the effect of 3α,5α-THP on neuroimmune protection in the brain.
Indexed as
Identifiers
41091171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.